4.7 • 7.3K Ratings
🗓️ 11 May 2020
⏱️ 131 minutes
🧾️ Download transcript
In this episode, Lew Cantley, Professor of cancer biology and Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College in NYC, walks us through his amazing discovery of phosphoinositide 3-kinase (PI3K) and the implications for the care of patients with cancer. He explains various combinations of therapies being tested and used, including the possibility of pairing prescriptive nutritional therapies to increase the efficacy of drugs like PI3K inhibitors. Lew also explains the metabolic nature of cancer through the lens of his research into the connection between sugar consumption, insulin resistance, and tumor growth. Additionally, Lew provides some details about his exciting new clinical trial that is just now enrolling patients with stage 4 breast cancer and endometrial cancer.
We discuss:
Learn more: https://peterattiamd.com/
Show notes page for this episode: https://peterattiamd.com/lewcantley/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.
Click on a timestamp to play from that location
0:00.0 | Hey everyone, welcome to the Drive Podcast. |
0:13.0 | I'm your host, Peter Atia. |
0:14.8 | This podcast, my website, and my weekly newsletter, all focus on the goal of translating |
0:18.7 | the science of longevity into something accessible for everyone. |
0:22.4 | Our goal is to provide the best content in health and wellness, full stop, and we've |
0:26.6 | assembled a great team of analysts to make this happen. |
0:29.4 | If you enjoy this podcast, we've created a membership program that brings you far more |
0:33.2 | in-depth content if you want to take your knowledge of this space to the next level. |
0:37.2 | At the end of this episode, I'll explain what those benefits are, or if you want to learn |
0:41.0 | more now, head over to peteratiamd.com forward slash subscribe. |
0:46.2 | Now, without further delay, here's today's episode. |
0:49.0 | I guess this week is Lou Cantley. |
0:52.4 | Lou is the Myer Director and Professor of Cancer Biology at the Sandra and Edward Myer |
0:56.3 | Cancer Center at Wild Cornel Medical College in New York City. |
1:00.1 | Lou's research has made significant advances in cancer research, stemming primarily from |
1:04.1 | his discovery of the signaling pathway for PI3 kinase, or PI3K in the mid-80s. |
1:11.3 | His results here have really touched multiple fields, including cancer first and foremost, |
1:16.6 | but also diabetes and autoimmune disease. |
1:19.9 | Lou is a very decorated scientist to put it mildly. |
1:24.2 | It would take me too long to rattle off all of the awards that he's won, but I'll leave |
1:28.2 | it to the four most prestigious, the Gerdner Award, the Breakthrough Prize in Science, |
1:33.0 | the Wolf Prize, and most recently the Horowitz Prize. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Peter Attia, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Peter Attia, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.